Table 1 Structure and systematic names of the studied drugs in the proposed MEKC and HPLC methods

a. Hydrochlorothiazide (HCT)

6-chloro-1, 1-dioxo-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide

9.09

b. Captopril (CPL)

(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl] pyrrolidine-2-carboxylic acid

4.02

c. Lisinopril (LSP)

(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]aminohexanoyl]

pyrrolidine-2-carboxylic acid

3.17, 10.21

d. Valsartan (VAL)

(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5yl) phenyl] phenyl] methyl] amino] butanoic acid

4.35

e. Atorvastatin (ATR)

(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1yl]-3,5-dihydroxyheptanoic acid

4.31

f. Amlodipine (AML)

3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

9.45

g. Bisoprolol (BSL)

1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol

9.67

h. Carvedilol (CVL)

1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol

8.74

i. Vincamine (VIC)

methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸^,1⁸.0^15,1⁹]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate

6.7, 10.52